Vrinda Bhat1, Megan McIntyre, Tracey Meyers. 1. Dr. Bhat is a Pharmacist Resident, Dr. McIntyre is a Medication Use Quality Manager, and Dr. Meyers is a Transplant Pharmacist, all in the Department of Pharmaceutical Services at Virginia Mason Medical Center in Seattle, Wash.
Abstract
PURPOSE: We evaluated the efficacy and safety of the current cytomegalovirus (CMV) prophylaxis regimen used at Virginia Mason Medical Center in Seattle. METHODS: A single-center, retrospective analysis was conducted in a regional renal transplantation center at a tertiary teaching facility. STUDY POPULATION: Seventy patients who underwent kidney and/or pancreas transplantation from October 2006 through December 2008 were observed for a period of six months after the procedure. Transplant recipients at risk for developing CMV disease received valganciclovir 450 mg daily. RESULTS: Outcome measures were incidence of CMV disease and incidence of severe leukopenia during the six-month postoperative period. Of 70 patients, seven (10%) developed CMV disease and five (7.1%) developed severe leukopenia while taking valganciclovir. Based on donor (D) and recipient (R) CMV serostatus, the incidence of CMV disease and severe leukopenia incidence was highest in the D+/R- group. Severe leukopenia developed in one patient with CMV disease who had a D+/R-kidney transplant. No statistical calculations were performed. CONCLUSION: The current lower-dose valganciclovir regimen at our institution was found to be efficacious and safe, and it provided significant cost savings.
PURPOSE: We evaluated the efficacy and safety of the current cytomegalovirus (CMV) prophylaxis regimen used at Virginia Mason Medical Center in Seattle. METHODS: A single-center, retrospective analysis was conducted in a regional renal transplantation center at a tertiary teaching facility. STUDY POPULATION: Seventy patients who underwent kidney and/or pancreas transplantation from October 2006 through December 2008 were observed for a period of six months after the procedure. Transplant recipients at risk for developing CMV disease received valganciclovir 450 mg daily. RESULTS: Outcome measures were incidence of CMV disease and incidence of severe leukopenia during the six-month postoperative period. Of 70 patients, seven (10%) developed CMV disease and five (7.1%) developed severe leukopenia while taking valganciclovir. Based on donor (D) and recipient (R) CMV serostatus, the incidence of CMV disease and severe leukopenia incidence was highest in the D+/R- group. Severe leukopenia developed in one patient with CMV disease who had a D+/R-kidney transplant. No statistical calculations were performed. CONCLUSION: The current lower-dose valganciclovir regimen at our institution was found to be efficacious and safe, and it provided significant cost savings.
Authors: Francis L Weng; Anup M Patel; Rimda Wanchoo; Yasmin Brahmbhatt; Kezia Ribeiro; Marc E Uknis; Shamkant Mulgaonkar; A Scott Mathis Journal: Transplantation Date: 2007-02-15 Impact factor: 4.939
Authors: Steven Gabardi; Colm C Magee; Steven A Baroletti; John A Powelson; Jennifer L Cina; Anil K Chandraker Journal: Pharmacotherapy Date: 2004-10 Impact factor: 4.705
Authors: S Brum; F Nolasco; J Sousa; A Ferreira; M Possante; J R Pinto; E Barroso; J R Santos Journal: Transplant Proc Date: 2008-04 Impact factor: 1.066
Authors: Fu L Luan; Linda J Stuckey; Jeong M Park; Daniel Kaul; Diane Cibrik; Akinlolu Ojo Journal: J Am Soc Nephrol Date: 2009-09-17 Impact factor: 10.121
Authors: C E Chamberlain; S R Penzak; R M Alfaro; R Wesley; C E Daniels; D Hale; A D Kirk; R B Mannon Journal: Am J Transplant Date: 2008-04-29 Impact factor: 8.086